IDNA - Technology Could Boost The NPV Of Biopharmaceutical Pipeline Assets Significantly

• Emerging technologies like gene editing, gene therapy, artificial intelligence AI, and next generation sequencing NGS should continue to improve clinical trial success rates, increasing the percentage of drug candidates that commercialize successfully.
• NGS, AI, CRISPR, and other gene therapies are likely to boost the efficiency of clinical trials, shorten development timelines, reduce failure rates, and increase returns on investment.
• In addition to increasing the odds of commercialization, technology also could enhance the value of drugs.

For further details see: